Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction-# Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash TransactionShare---Divestiture streamlines operations and advances the Company's strategy to fully exit non-core activitiesLOS ANGELES--([BUSINESS WIRE])-- [Niagen Bioscience, Inc.](NASDAQ: NAGE), the global authority on NAD+ (nicotin ...

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous and injectable formulations. Rob Fried, CEO of Niagen Bioscience, commented, " ...

Financial Performance - Total company net sales reached $34 million in Q3 2025, a 33% increase year-over-year[10] - Tru Niagen® net sales were $26 million in Q3 2025, up 44% year-over-year[10] - Gross margin improved to 64.5% in Q3 2025, a 100 basis points increase year-over-year[10] - Net income was $4.6 million, or $0.06 earnings per share, an increase of $2.7 million and $0.04 year-over-year[10] - Adjusted EBITDA reached $6.4 million, up $3.5 million year-over-year[10] - Cash provided from operations year-to-date was $12.8 million, with $64.3 million in cash and no debt[10] Sales Mix and Growth - Tru Niagen® net sales accounted for 77% of total net sales in Q3 2025, compared to 71% in Q3 2024[28] - Niagen®-related net sales remained at 97% of total net sales in both Q3 2025 and Q3 2024[28] - Year-to-date net sales reached $99.6 million, a 36% increase year-over-year[34] Outlook - The company reaffirmed its increased full-year 2025 net sales growth outlook to between 25% and 30%, driven by strong momentum in Tru Niagen® and Niagen® ingredients[10]

Financial Performance - Q2 2025 - Total company net sales reached $31.1 million, a 37% year-over-year increase[10] - Tru Niagen® net sales were $22.7 million, representing a 22% year-over-year increase[10] - Niagen® ingredient sales surged to $7.4 million, marking a 135% year-over-year increase[10] - Gross margin improved to 65.0%, up 480 basis points year-over-year[10] - Net income was $3.6 million, or $0.05 earnings per share, a $3.6 million year-over-year increase[10] - Adjusted EBITDA reached $5.0 million, a $3.5 million year-over-year increase[10] Financial Position - Cash provided from operations year-to-date was $9.1 million, with a cash balance of $60.5 million and no debt[10] Sales Mix - Q2 2025 - E-commerce accounted for 57% of net sales, while Watson's & Other B2B represented 25%[26] - Food-grade Niagen® contributed 14% to net sales, and Analytical Reference Standards & Services accounted for 3%[26] - Other Ingredients made up 1% of net sales[26] 2025 Outlook - The company anticipates net sales growth between 22% and 27% year-over-year[10] - Sales and marketing expenses are expected to increase in absolute dollars but decrease as a percentage of net sales year-over-year[10]

Financial Highlights - ChromaDex's total net sales reached $83.5 million in 2023, with Tru Niagen® sales contributing $69.5 million[14] - Tru Niagen® sales experienced a 52% Compound Annual Growth Rate (CAGR)[11] - E-commerce net sales reached $51.2 million in 2023, demonstrating an 85% CAGR[16] - Gross margin increased from 49.4% to 60.8% following a strategic shift towards Tru Niagen®[17] - ChromaDex reported a positive Adjusted EBITDA of $1.9 million in 2023[11, 12] Market and Product - ChromaDex identifies as the global authority on NAD+ with a Total Addressable Market (TAM) exceeding $500 billion across human and pet nutrition, cosmetics, and pharmaceuticals[11] - Tru Niagen® is identified as a proprietary NAD+ boosting supplement[11] - Approximately 60% of ChromaDex's business is attributed to e-commerce[15] - North America accounts for 75% of Tru Niagen® net sales, followed by APAC with 22%[56] Research and Development - ChromaDex has invested in over $100 million of third-party research supporting the benefits of its proprietary ingredient[11] - ChromaDex holds a strong intellectual property portfolio, including over 80 patents for Niagen® and other NAD+ precursors[11]

Company Overview - ChromaDex is a global authority on NAD+ with a strong intellectual property portfolio for Niagen® and other NAD precursors[8] - The company has strategic partnerships with blue chip companies and a strong financial position, with $4 million LTM Adjusted EBITDA and $28 million in cash as of June 30, 2024[8] - ChromaDex's LTM revenue ended June 2024 was $856 million, with a net loss of $14 million and non-GAAP Adjusted EBITDA of $4 million[25] Consumer Health (Tru Niagen®) - Tru Niagen® has proven to be a proprietary NAD+ boosting supplement with LTM sales of over $80 million[8] - E-commerce represents approximately 60% of the Tru Niagen® business[34] - Annual e-commerce net sales have grown at a CAGR of 85% from 2017 to 2023[35], reaching $512 million in 2023[35] - Gross margin increased from 494% to 608% since the strategic pivot to focus on the consumer product, Tru Niagen®[36] IV & Injectables (Niagen®+) - The company estimates the incumbent NAD+ IV retail market in North America is worth at least $100 million[49] - Niagen®+ IV offers competitive advantages over NAD+ IV, including 75% faster infusion time and minimal side effects[50] Pharmaceutical - ChromaDex is pioneering the development of Parkinson's Disease treatment, with a Phase III study underway involving 400 participants supplemented with NR for 12 months at a 1000mg daily dose, with results expected in 2025[59, 60] Financial Outlook - The company projects net sales growth between 10%-15% year-over-year for 2024[69]

Financial Performance - Q1 2025 - Total company net sales reached $30.5 million, a 38% increase year-over-year (YoY)[10] - Tru Niagen® net sales were $21.5 million, up 24% YoY[10] - Niagen® ingredient sales increased significantly to $8.0 million, a 95% YoY increase[10] - Gross margin improved to 63.4%, a 270 basis points increase YoY[10] - Net income was $5.1 million, or $0.07 earnings per share, an increase of $5.6 million and $0.08 YoY[10] - Adjusted EBITDA was $4.9 million, up $4.2 million YoY[10] - The company ended the quarter with $55.6 million in cash and no debt, with cash provided from operations at $7.9 million year-to-date[10] Sales Mix - Q1 2025 - E-commerce accounted for 58% of net sales in Q1 2025, compared to 55% in Q1 2024[26] - Watson's & Other B2B represented 20% of net sales in Q1 2025, up from 16% in Q1 2024[26] - Food-grade Niagen® contributed 19% of net sales in Q1 2025, down from 23% in Q1 2024[26] - Tru Niagen® net sales accounted for 71% of total net sales in Q1 2025, compared to 78% in Q1 2024[27] - Niagen®-related net sales remained at 97% of total net sales in both Q1 2025 and Q1 2024[27] Financial Outlook - 2025 - The company adjusted its full-year 2025 net sales growth outlook to between 20%-25%, previously approximately 18%[10] - Adjusted general and administrative expenses outlook was revised upwards by $7.0 to $8.0 million, previously $5.0 to $6.0 million[10]

Financial Performance - Q4 2024 - Total company net sales reached $29.1 million, a 37% year-over-year increase[11] - Tru Niagen® net sales amounted to $22.7 million, representing a 29% year-over-year growth[11] - Niagen® ingredient sales experienced substantial growth, reaching $5.3 million, a 96% year-over-year increase[11] - Gross margin improved to 62.5%, a 150 basis points increase compared to the previous year[11] - Net income significantly increased to $7.2 million, a $7.1 million increase year-over-year[11] - Adjusted EBITDA nearly tripled, reaching $3.4 million compared to $1.2 million in Q4 2023[11] Financial Performance - Full Year 2024 - Total net sales grew by 19% year-over-year[11] - Net income reached $8.6 million, or $0.11 earnings per share, compared to a net loss of $4.9 million, or $0.07 loss per share in the previous year[11] - Operating cash flows amounted to $12.1 million, with a year-end cash balance of $44.7 million and no debt[11] - Adjusted EBITDA increased to $8.5 million, up from $1.9 million in FY 2023[11] 2025 Outlook - The company anticipates continued revenue growth of approximately 18% year-over-year[11]